Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection
International Journal of Infectious Diseases · 2023
DOI: 10.1016/j.ijid.2023.01.035 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Infectious Diseases, 2023. Verfasst von Szu-Ting Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Daptomycin, Bacteremia, Vancomycin-Resistant Enterococci, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare, Ministry of Science and Technology, Taiwan, National Taiwan University Hospital.
Abstract (Originalsprache)
OBJECTIVES: We analyzed the risk factors affecting linezolid treatment outcome in vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI). METHODS: We conducted a multicenter observational study of patients who received linezolid 600 mg every 12 hours for VRE BSI. The primary outcome was 28-day mortality. The estimated area under the concentration-time curve and trough concentration were calculated. Multivariable logistic regression was used for the outcome analysis. RESULTS: A total of 170 patients were included: 114 (67.1%) survived and 56 (32.9%) did not. A total of 26 (18.2%) isolates showed a linezolid minimum inhibitory concentration (MIC) of ≤1 mg/l, 113 (79.0%) of 2 mg/l, and 4 (2.8%) of 4 mg/l. The univariable analysis showed that the linezolid MIC and concentration-time curve/MIC were not associated with mortality (P = 0.95 and P = 0.42, respectively). After adjusting for underlying comorbidity and disease severity, the linezolid dose per body weight (LDBW), body height, and interaction between them were independent risks for mortality. Marginal analysis showed that increasing the LDBW was protective in patients with a body height 12.2 mg/l was a risk factor for thrombocytopenia. CONCLUSION: The LDBW and body height were interactively associated with clinical outcomes of linezolid treatment for VRE BSI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: weischuang@gmail.com.
Förderung
- Ministry of Health and Welfare
- Ministry of Science and Technology, Taiwan
- National Taiwan University Hospital
Zitieren
APA
Huang, S. T., Yang, J. L., Lin, C. Y., Huang, S. H., Wang, J. T., Chuang, Y. C., Chen, Y. C., & Chang, S. C. (2023). Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection. International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2023.01.035
Vancouver
Huang ST, Yang JL, Lin CY, Huang SH, Wang JT, Chuang YC, et al. Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection. International Journal of Infectious Diseases. 2023. doi:10.1016/j.ijid.2023.01.035
BibTeX
@article{Huang2023,
author = {Huang, Szu-Ting and Yang, Jia-Ling and Lin, Chi-Ying and Huang, Sung-Hsi and Wang, Jann-Tay and Chuang, Yu-Chung and Chen, Yee-Chun and Chang, Shan-Chwen},
title = {Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection},
journal = {International Journal of Infectious Diseases},
year = {2023},
doi = {10.1016/j.ijid.2023.01.035}
}
EUVIMED